Navigation Links
Breast cancer treatment resistance linked to signaling pathway

PHILADELPHIA -- Activation of the Src signaling pathway may cause resistance to standard medical treatment in some patients with breast cancer, and inhibition of this pathway holds the potential to overcome that resistance, according to data presented here at the American Association for Cancer Research Molecular Diagnostics in Cancer Therapeutic Development meeting.

"If this finding is confirmed in clinical trials, which are currently being designed, then inhibiting Src signaling while giving standard of care medical treatment might allow us to overcome some aspects of drug resistance in the clinic," said Christina M. Coughlin, M.D., Ph.D., medical director and global medical monitor at Wyeth Pharmaceuticals, who lead this research in Wyeth's Department of Discovery Translational Medicine.

The identification of genetically altered pathways in human tumors, and their subsequent inhibition, has become a major treatment strategy in many cancers. Herceptin, also known as trastuzumab, targeted HER2 in patients with breast cancer and was one of the first therapies to use this approach. Now, many newer cancer drugs have labeling to help oncologists identify patients based on expression of the drug target.

Some known pathways have no genetic events to help identify patients. Src is one of the oldest known oncogenes, active in many human cancers but with no known predisposing genetic event. Coughlin said researchers suspected that some part of its pathway, either downstream or upstream, may be driving tumor development and treatment resistance. Understanding which parts of the pathway to measure in human tumors is key to developing molecular diagnostics that could eventually allow oncologists to select appropriate patients for a Src inhibitor in the clinic.

For the current study, Coughlin and colleagues performed quantitative tissue microarray sampling among almost 650 patient samples to analyze for the expression of markers of the Src pathway.

According to Coughlin, the patients represented the entire spectrum of breast cancer, and researchers identified subsets of patients with high Src activation who expressed low levels of estrogen receptor, progesterone receptor and HER2, also known as triple negative breast cancer, as well as subsets expressing the estrogen or progesterone receptors.

These patient sets had lower overall survival associated with expression of Src signaling pathway biomarkers, which suggests that Src pathway activation may have played a role in treatment resistance.

"This gives us all the pieces to the puzzle. This type of cancer signaling pathway study holds the potential to help determine who the appropriate patients are for the newer targeted drugs that we have to treat breast cancer in the absence of genetic signals for a given drug target. We can then translate that information into molecular diagnostics that can be applied within the clinical trials," Coughlin said.


Contact: Jeremy Moore
American Association for Cancer Research

Related biology news :

1. Newly created cancer stem cells could aid breast cancer research
2. Linchpin gene may be useful target for new breast cancer therapies
3. Dietary calcium could possibly prevent the spread of breast cancer to bone
4. Researchers find new gene linked to breast cancer
5. Analysis of breast and colon cancer genes finds many areas of differences between tumors
6. Genome update defines landscape of breast and colon cancers
7. AACR, BCRF award inaugural grants in translational breast cancer research
8. Enhanced DNA-repair mechanism can cause breast cancer
9. Einstein researchers receive grants totaling $700,000 for innovative breast cancer research
10. Breast cancer research and inkjet tissue printing get NSF boost
11. Breastfeeding boost IQ in infants with helpful genetic variant
Post Your Comments:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... DUBAI , UAE, May 9, 2016 ... choice when it comes to expanding freedom for high ... Even in today,s globally connected world, there ... online conferencing system could ever duplicate sealing your deal ... are obtaining second passports by taking advantage of citizenship ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
Breaking Biology Technology: